… older adults, and immunosuppressed individuals 15 , especially … into the Molnupiravir and
Nirmatrelvir-Ritonavir treatment groups… , as participants were censored at first event of interest. …

… 19, the percentage of unvaccinated participants who had been … phase, primary or acquired
immunodeficiency), which have … not treated with oral antiviral medications, we believe that …

… Molnupiravir and Nirmatrelvir-ritonavir treatment within 5 days of symptom onset was
associated with a lower risk of in-hospital death compared with control subjects. The use of these …

… of molnupiravir treatment both for the molnupiravir group and … less likely to be treated with
molnupiravir in comparison to … disease, malignancy, and immunosuppression were each an …

… /failure), severely immunocompromised persons who are not … day 29 of 1 participant treated
with molnupiravir 400 mg and 1 … of molnupiravir in the hospitalized participants studied: …

… from AstraZeneca and participation on advisory board for … death, yet treatment strategies for
immunocompromised patients … treatment on inpatient mortality among immunocompromised …

… clinical subgroups being underrepresented (such as immunosuppressed individuals). Several
real-… between participants treated with Paxlovid and sotrovimab or molnupiravir (Figure 1). …

… ) and immunocompromised status (yes … treatment-related AEs were rash (<1% [1/483] and
<1% [2/486]) and diarrhea (<1% [2/483] and 0% [0/486]). Four participants in the molnupiravir …

… Design, Setting, and Participants This was a cohort study of … Patients who were
immunocompromised or who had … number of patients treated with nirmatrelvir or molnupiravir, it …

… for molnupiravir treatment included the following: (1) those aged ≥60 years; (2) those aged
≥18 years and are immunocompromised … , most of the participants in the PANORAMIC trial …